LeMaitre Vascular, Inc. (NASDAQ:LMAT – Get Rating) – Analysts at Barrington Research lowered their Q2 2022 EPS estimates for LeMaitre Vascular shares in a report published on Friday, April 29. Barrington Research analyst M. Petusky now expects the medical instrument maker to report earnings of $0.31 per share for the quarter, down from his previous forecast of $0.39. represents dollars. Barrington Research also released estimates for LeMaitre Vascular’s earnings of $0.32 per share for the third quarter of 2022, $0.34 per share for the fourth quarter of 2022, $1.24 per share for the fiscal year 2022, and $1.24 per share for the first quarter of 2023 from $0.31 per share, second quarter 2023 from $0.36 per share, third quarter 2023 from $0.34 per share, fourth quarter Earnings for 2023 are $0.38 per share, earnings for fiscal 2023 at $1.40 per share and earnings for fiscal 2024 at $1.55 per share.
LMAT has been the subject of several other research reports. Zacks Investment Research has upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating and set a price target of $50.00 for the company in a report Thursday. StockNews.com reported on LeMaitre Vascular shares in a research note on Thursday, March 31st. You give the stock a “hold” rating. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of Buy and a consensus target of $57.00.
Shares of LMAT opened at $43.21 on Monday. The company has a market cap of $948.55 million, a PE ratio of 34.57, a PEG ratio of 3.29 and a beta of 1.32. The company’s 50-day moving average stands at $45.73. LeMaitre Vascular has a 1-year low of $39.48 and a 1-year high of $64.50.
LeMaitre Vascular (NASDAQ:LMAT – Get Rating) last released its quarterly earnings data on Thursday, April 28th. The medical instrument maker reported earnings per share (EPS) of $0.27 for the quarter, beating Thomson Reuters consensus estimate of $0.28 ($0.01). The company had revenue of $39.56 million for the quarter, compared to analysts’ expectations of $38.65 million. LeMaitre Vascular had a net margin of 17.09% and a return on equity of 11.76%. The company’s revenue for the quarter rose 10.2% year over year. In the same period last year, the company generated earnings per share of $0.28.
Several institutional investors have recently changed their positions in the company. BlackRock Inc. added 1.0% to its position in LeMaitre Vascular in the fourth quarter. BlackRock Inc. now owns 3,147,424 shares of the medical instrument maker valued at $158,097,000 after purchasing an additional 31,590 shares during the period. Conestoga Capital Advisors LLC increased its holding in LeMaitre Vascular by 1.2% during the first quarter. Conestoga Capital Advisors LLC now owns 1,879,847 shares of the medical instrument company valued at $87,357,000 after purchasing an additional 22,663 shares during the period. Copeland Capital Management LLC increased its position in LeMaitre Vascular by 0.8% during the first quarter. Copeland Capital Management LLC now owns 1,215,005 shares of the medical instrument maker worth $56,461,000 after purchasing an additional 9,806 shares last quarter. Ranger Investment Management LP increased its position in LeMaitre Vascular by 1.6% during the fourth quarter. Ranger Investment Management LP now owns 646,999 shares of the medical instrument maker, valued at $32,499,000, after purchasing an additional 10,010 shares last quarter. Finally, Summit Creek Advisors LLC increased its stake in LeMaitre Vascular by 21.0% during the fourth quarter. Summit Creek Advisors LLC now owns 361,359 shares of the medical instrument maker, valued at $18,151,000, after purchasing an additional 62,754 shares last quarter. Institutional investors and hedge funds own 85.82% of the company’s shares.
In related news, insider Trent G. Kamke sold 7,929 shares of LeMaitre Vascular in a transaction on Wednesday, March 2nd. The shares sold at an average price of $48.22 for a total transaction of $382,336.38. The sale was disclosed in a legal filing with the SEC, which can be accessed at this link. Company insiders own 16.50% of the company’s shares.
The company also recently announced a quarterly dividend, which will be paid on Thursday, June 2nd. Stockholders of record on Tuesday, May 17 will receive a dividend of $0.125. That equates to an annual dividend of $0.50 and a yield of 1.16%. The ex-dividend date is Monday May 16th. LeMaitre Vascular’s RTP is 40.00%.
About LeMaitre Vascular (received rating)
LeMaitre Vascular, Inc develops, markets, sells, services and supports medical devices and implants used to treat peripheral vascular diseases worldwide. It offers an angioscope, a fiber optic catheter used to view the lumen of a blood vessel; embolectomy catheters for removing blood clots from arteries or veins; occlusion catheters, which temporarily occlude blood flow; perfusion catheters for perfusing blood and other fluids into the vascular system; and thrombectomy catheters having a silicone balloon for removing thrombi in the venous system.
Receive news and reviews for LeMaitre Vascular Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for LeMaitre Vascular and related companies with MarketBeat.com’s FREE daily email newsletter.